WallStSmart
ENTX

Entera Bio Ltd

NASDAQ: ENTX · HEALTHCARE · BIOTECHNOLOGY

$1.29
-1.57% today

Updated 2026-06-02

Market cap
$58.16M
P/E ratio
P/S ratio
1,547.08x
EPS (TTM)
$-0.26
Dividend yield
52W range
$1 – $3
Volume
0.2M

Entera Bio Ltd (ENTX) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20152016201720182019202020212022202320242025
Operating cash flow$-3.50M$-3.14M$-4.53M$-9.80M$-8.92M$-10.56M$-9.06M$-12.50M$-7.31M$-6.82M$-7.37M
Capital expenditures$54000.00$41000.00$51000.00$68000.00$40000.00$53000.00$17000.00$46999.00$17000.00$3000.00$107000.00
Depreciation
Stock-based comp$366000.00$1.49M$4.88M$1.23M$1.48M$901000.00$1.86M$2.25M$1.69M$2.56M$2.75M
Free cash flow$-3.55M$-3.18M$-4.58M$-9.86M$-8.96M$-10.61M$-9.08M$-12.55M$-7.33M$-6.82M$-7.48M
Investing cash flow
Financing cash flow
Dividends paid
Share repurchases
Debt repayment
Net change in cash

Frequently asked questions

How profitable is ENTX?

In its most recent fiscal year, ENTX ran a gross margin of -71.43%, an operating margin of -27,450.00%, and a net margin of -27,235.71%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does ENTX generate?

ENTX produced $-7.48M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is ENTX's balance sheet healthy?

ENTX holds $7.11M in cash and equivalents against — in long-term debt, on $13.10M of shareholder equity. That debt is best read against the cash flow the business throws off each year.